Dr. Peppa

What is pentadeca arginate (PDA), and is it just BPC-157?

Published by Dr. Peppa ·

Disclosure: Dr. Peppa is owned and operated by Medtruva LLC, which sells peptide products, including some compounds discussed on this site. Advertisements are labeled.

The short answer

  • Same peptide, different salt. PDA is an arginine salt of BPC-157, the same 15-amino-acid sequence with a different counterion.
  • "Pentadeca arginate" is a marketing name. No FDA document uses it. No published study uses it. No registered clinical trial uses it.
  • The stability claims trace to one patent, written by the party seeking the patent. The widely repeated "1,000 times more stable" figure has no source we could find.
  • It is not on any FDA compounding list — but neither is BPC-157, and absence from a list is not permission.

Where PDA came from

In September 2023, FDA placed BPC-157 in the category of substances that "may present significant safety risks," which closed the compounding pathway for it. Products under the name pentadeca arginate began appearing in the market after that, and the earliest dated vendor pages we could verify are from 2025.

The chemistry itself is older. A 2013 patent, granted in 2017 to a Croatian company, claims arginine salts of the same pentadecapeptide, naming "bepecin di-L-arginine salt."

So the molecule is not new. The commercial name is.

Is it the same as BPC-157?

The peptide is the same. The salt is different.

A salt pairs the active molecule with a counterion, in this case arginine rather than acetate. FDA's framing, from its July 2026 briefing document, is that "a free base or the various salts or ester forms of an active moiety are distinct APIs, each with a different chemical structure."

That's why both statements circulating online are half-right. It is technically a distinct drug substance. It is also the same active peptide.

What's actually documented

The stability data exists, with a caveat. The patent includes comparisons of the arginine salt against the acetate form: in solid form under heat and humidity, in solution, and in simulated gastric acid. The arginine salt held up better in all three.

Two things to hold alongside that:

Nothing else is documented. Our searches found:

The underlying compound isn't well understood either. FDA's briefing says "the molecular targets for BPC-157 have not been identified."

The claims sellers make

These appear on compounding pharmacy and clinic pages. We're reporting that the claims are made, not that they're true:

Claim What the record shows
More stable than BPC-157 acetate Supported for chemical stability, by the patent's own data only
Better bioavailability, "superior therapeutic profile" No pharmacokinetic data on the arginate exists
Orally bioavailable Not established. Surviving acid in a test tube isn't absorption
Safer than BPC-157 No comparative safety data of any kind
"Not on the FDA restricted list" Technically true, and misleading. Nothing authorizes it either
Sourced from "FDA-approved pharmacies" Pharmacies are licensed, not FDA-approved. No PDA product is FDA-approved

The regulatory position

As of the current 503A list, updated May 14, 2026, the restricted category contains six substances, and BPC-157 is not among them. It sits instead under "nominated but withdrawn."

That's not an opening. Under federal law a compounding pharmacy may use a bulk substance only if it has a USP monograph, is a component of an approved drug, or appears on the bulks list. FDA states there is no USP monograph for BPC-157 free base or its acetate. There isn't one for an arginate salt either.

In July 2026 an advisory committee voted 8–6 with one abstention to recommend adding BPC-157 to the list. That vote is non-binding and no rule has followed.

In sport: BPC-157 is prohibited under the World Anti-Doping Agency's non-approved substances category. Anti-doping bodies haven't published anything specific to the arginate salt, so if you compete, ask your own anti-doping organization rather than relying on the name being different.

The bottom line

PDA is a decade-old salt of a compound that lost its compounding pathway, given a new commercial name.

The strongest accurate statement about it is a negative one: no published studies, no trials, no pharmacokinetic data, no regulatory recognition, and a parent compound whose mechanism FDA says is unidentified. The one thing with documentation behind it, chemical stability, comes from a patent rather than a journal.

Sources